Simon Boge Brant - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Journal of Applied Statistics|July 12, 2023

The fraud loss for selecting the model complexity in fraud detectionSimon Boge Brant, Ingrid Hobæk Haff

Acta Oncologica (Stockholm, Sweden)|October 6, 2023

Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancerSiri Børø, Steinar Thoresen, Simon Boge Brant, et al.

Clinical Pharmacology and Therapeutics|February 7, 2025

Comparative Effectiveness of First-Line Pembrolizumab vs. Chemotherapy in aNSCLC: A Norwegian Population-Based Cohort StudySimon Boge Brant, Siri Børø, Christian Jonasson, et al.

Pharmacoepidemiology and Drug Safety|June 24, 2025

Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung CancerEuloge Clovis Kenne Pagui, Simon Boge Brant, Kristian Svendsen, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Journal of Applied Statistics|July 12, 2023

The fraud loss for selecting the model complexity in fraud detectionSimon Boge Brant, Ingrid Hobæk Haff

Acta Oncologica (Stockholm, Sweden)|October 6, 2023

Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancerSiri Børø, Steinar Thoresen, Simon Boge Brant, et al.

Clinical Pharmacology and Therapeutics|February 7, 2025

Comparative Effectiveness of First-Line Pembrolizumab vs. Chemotherapy in aNSCLC: A Norwegian Population-Based Cohort StudySimon Boge Brant, Siri Børø, Christian Jonasson, et al.

Pharmacoepidemiology and Drug Safety|June 24, 2025

Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung CancerEuloge Clovis Kenne Pagui, Simon Boge Brant, Kristian Svendsen, et al.

Pageof 1